Clinical Study of CoV-2 mRNA Vaccine for High Risk Populations
Latest Information Update: 30 Mar 2020
At a glance
- Drugs MRNA Coronavirus vaccine eTheRNA Immunotherapies (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 30 Mar 2020 New trial record
- 24 Mar 2020 According to an eTheRNA Immunotherapies media release, eTheRNA and its partners EpiVax, Nexelis, REPROCELL and CEV have extensive experience in the mRNA vaccine field and this will help accelerate progress towards clinical trials with patient enrolment expected in early 2021.